Adam Kenney
Interventional Pain Medicine · Newark, NJNPI 1083956114
Payments from drug & device makers
What this record shows
This record is dominated by grants: $3,000 of the $4,910 with a category attached, or 61.1%. Medtronic accounts for 63.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $3,352 and has fallen 83.2% since, to $563 in 2025.
Across 92 payments — averaging $53.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Scilex Pharmaceuticals Inc.$361
- Zynex Medical, Inc.$277
- Collegium Pharmaceutical, Inc.$197
- Abbott$194
- Boston Scientific$174
- plus $610 from 12 others
What the payments were for
- Grants$3,00061%
- Food & beverage$1,91039%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $3,097 |
| Scilex Pharmaceuticals Inc. | 40 | $361 |
| Zynex Medical, Inc. | 1 | $277 |
| Collegium Pharmaceutical, Inc. | 15 | $197 |
| Abbott | 4 | $194 |
| Boston Scientific | 2 | $174 |
| Nevro Corp. | 1 | $135 |
| AbbVie | 8 | $127 |
| Relievant Medsystems, Inc. | 2 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Biotronik NRO, Inc. | 2 | $53 |
| IBSA Pharma Inc. | 2 | $51 |
| UCB, Inc. | 2 | $35 |
| Si-bone, Inc. | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $15 |
| International Rehabilitative Sciences, Inc | 1 | $15 |
| Valinor Pharma, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$3,000
- Nexwave$277
- WAVEWRITER ALPHA$161
- PROCLAIM$139
- Omnia$135
How this compares
$4,910 in reported general payments places this provider in the 60th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 23 | $11,220 |
| Buprenorphine | 68 | $9,802 |
| ZtlidoLidocaine | 13 | $8,775 |
| Diclofenac Sodium | 115 | $6,409 |
| Pregabalin | 342 | $5,899 |
| Lidocaine | 17 | $2,886 |
| Duloxetine Hcl | 184 | $2,155 |
| Gabapentin | 228 | $1,917 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 157 | $1,629 |
| Cyclobenzaprine Hcl | 53 | $877 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 35 | $870 |
| Methocarbamol | 67 | $720 |
| Baclofen | 44 | $585 |
| Oxycodone Hcl | 73 | $568 |
| Naproxen | 45 | $267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $197 | $11,22023 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $361 | $8,77513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 82 interventional pain medicine providers in New Jersey.
Other interventional pain medicine in Newark
- Andrew KaufmanNewark$9K
- Youssef JosephsonWest Deptford$496K
- Ali ValimahomedHolmdel$415K
- Saurabh DangEdgewater$157K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Steve AydinFranklin Lakes$22K
- Kieran SlevinHainesport$21K
- John CoccaroToms River$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.